Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

Post time 2024-4-30 15:38:13

journal：Journal of Clinical Oncology

Authors：Aditya Bardia; Ian E. Krop; Takahiro Kogawa; Dejan Juric; Anthony W. Tolcher; Erika P. Hamilton; Toru Mukohara; Aaron Lisberg; Toshio Shimizu; Alexander I. Spira; Junji Tsurutani; Senthil Damodaran; Kyriakos P. Papadopoulos; Jonathan Greenberg; Fumiaki Kobayashi; Hong Zebger-Gong; Rie Wong; Yui Kawasaki; Tadakatsu Nakamura; Funda Meric-Bernstam

Published date：--

DOI：10.1200/jco.23.01909

PDF link：https://ascopubs.org/doi/pdfdirect/10.1200/JCO.23.01909

Article link：http://dx.doi.org/10.1200/jco.23.01909

Article Source：American Society of Clinical Oncology (ASCO)。

Remark：

Post time 2024-4-30 15:38:14

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Other] Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study